Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meifeng Tu

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Hematology & Oncology|June 25, 2015
Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosisXin Cao, Qing Ye, Robert Z Orlowski, et al.
BMC Cancer|February 26, 2021
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignanciesZhitao Ying, Ting He, Xiaopei Wang, et al.
Blood|January 20, 2017
Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman diseaseLi Yu, Meifeng Tu, Jorge Cortes, et al.
Nature Medicine|April 24, 2019
A safe and potent anti-CD19 CAR T cell therapyZhitao Ying, Xue F Huang, Xiaoyu Xiang, et al.
Oncotarget|June 28, 2015
Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countriesZijun Y Xu-Monette, Meifeng Tu, Kausar J Jabbar, et al.
Oncotarget|March 12, 2015
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countriesZijun Y Xu-Monette, Meifeng Tu, Kausar J Jabbar, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.
Blood|March 2, 2013
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Zijun Y Xu-Monette, Alexander Tzankov, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Hematology & Oncology|June 25, 2015
Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosisXin Cao, Qing Ye, Robert Z Orlowski, et al.
BMC Cancer|February 26, 2021
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignanciesZhitao Ying, Ting He, Xiaopei Wang, et al.
Blood|January 20, 2017
Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman diseaseLi Yu, Meifeng Tu, Jorge Cortes, et al.
Nature Medicine|April 24, 2019
A safe and potent anti-CD19 CAR T cell therapyZhitao Ying, Xue F Huang, Xiaoyu Xiang, et al.
Oncotarget|June 28, 2015
Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countriesZijun Y Xu-Monette, Meifeng Tu, Kausar J Jabbar, et al.
Oncotarget|March 12, 2015
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countriesZijun Y Xu-Monette, Meifeng Tu, Kausar J Jabbar, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.
Blood|March 2, 2013
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Zijun Y Xu-Monette, Alexander Tzankov, et al.
Pageof 4